1 not yet recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Not yet recruiting 1 |
Follow chenxu: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC Probiotic, Disitamab Vedotin, Toripalimab - Muscle Invasive Bladder Cancer (MIBC) | Phase 2 | Not yet recruiting | chenxu | 146 | 2026-03-26 | 2026-03-17 |
Probiotics (1) · disitamab vedotin (1) · toripalimab (1)
China (1)